A powerful bipartisan coalition in the Senate is pushing forward the INSULIN Act of 2026, legislation that would cap insulin costs at just $35 per month for both insured and uninsured Americans starting in 2027 - a move that could save millions of diabetic Americans from the predatory pricing schemes of Big Pharma.
The renewed momentum behind this critical legislation comes as President Trump's second-term agenda continues to deliver wins for everyday Americans. Unlike the swamp's typical approach of protecting corporate donors, this administration is actually taking on the pharmaceutical giants that have been bleeding hardworking families dry.
For too long, Americans have been forced to choose between paying rent and paying for life-saving insulin - while the same medication costs a fraction of the price in other countries. How is it that the greatest nation on Earth allows its citizens to ration medication or cross borders just to afford basic healthcare?
Real Relief for Real Americans
This isn't just another Washington talking point - this is about real families facing real crises. We're talking about diabetics who've been forced to ration insulin, parents who've watched their children suffer, and seniors choosing between medications and groceries.
The bipartisan nature of this bill shows that when it comes to taking on corporate greed, Americans can unite across party lines. But let's be clear: this momentum exists because we have a president who isn't afraid to challenge the pharmaceutical lobby that owns so many politicians in the swamp.
"The American people deserve affordable healthcare, not corporate price-fixing schemes that put profits over patients."
Big Pharma has had decades to do the right thing voluntarily. Instead, they've chosen to maximize profits while Americans suffer. It's time for Congress to step up and put patients before pharmaceutical company stock prices.
Will your senators stand with diabetic Americans, or will they bow to Big Pharma's lobbyists? The choice couldn't be clearer.